

TO THE NATIONAL SECURITIES MARKET COMMISSION (CNMV)

For the purposes set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and related provisions, Faes Farma, S.A. hereby announces the following

OTHER RELEVANT INFORMATION

Presentation of Faes Farma's 9-month results

Attached is a presentation with Faes Farma's nine-month results.

A webcast with analysts and investors will be held today at 10:30 a.m. (CET), featuring Valentin Ruiz and Iker Etxezarreta (CFOs) and María Marín (Head of IR & ext. Comms.). Following the presentation, there will be a question and answer session via the webcast.

To follow the conference call via webcast, please register at the following link:
<https://streamstudio.world-television.com/1506-2832-42358/es>

The recording of the webcast will be available on the Faes Farma website, in the investors section: www.faesfarma.com

Leioa, 4 November 2025



REPORT 9M 2025

Faes Farma



INDEX

1/

Highlights and key figures

2/

**Business evolution
9M 2025**

3/

9M 2025 results and outlook




1/

Highlights and key figures



Highlights 9M 2025



BUSINESS

- / Total revenues +15.5% (+10.6% excluding M&A), in the high guidance range, driven by growth in **all business areas**.
- / Pharma revenues +13%, with the **LATAM** market (**+16%**) and **Licences (+17%)** being the main growth drivers.
- / Adjusted EBITDA +3% excluding Derio's one-off costs and M&A results.

R&D

- / Approval of pediatric bilastine in Europe **<6 years old**.
- / Dossier validated and first round of questions completed with the Reporting Member State for the evaluation of **Mesalazine 1.5 g gastro-resistant tablets**.
- / Completion of 3 bioequivalence clinical trials and commencement of a new one.
- / Approval of Akantior reimbursement in Spain.

Financial situation

- / Payment of the full 2024 dividend in **January and July** (51% pay out).
- / Disbursement of **bank financing** while maintaining a comfortable liquidity position at Group level.

Other

- / **Group's New Strategic Plan 2025-2030.**
- / Acquisition of **Laboratorio Edol** in June.
- / Acquisition of **SIFI, S.P.A.** in September.
- / With the new additions, the **Global Executive Team** is now complete as a management body.

Key figures 9M 2025



*Adjusted EBITDA: ex M&A and excluding extraordinary costs from Derio

2/

Business evolution 9M 2025



Balanced growth across all areas of the Group


Revenues by portfolio line

	9M 2025	9M 2024	%
Pharma	399.5	352.4	13%
Pharma top 3 molecules	176.7	153.5	15%
Rest of Pharma	222.8	198.9	12%
Animal Nutrition and Health	57.8	39.1	48%
Other*	-3.3	1.4	
Total	454.0	392.9	16%

* non-commercial income and exchange rate impact

Rounded data

Revenues by portfolio line



Highlights of the main molecules

Very positive evolution with excellent performance in both direct sales and Licences

Bilastine



112.4 M€

The strong performance we saw in the first half of the year continues, with growth of **+11%** and positive results in all areas, particularly in our international subsidiaries.

Calcifediol



47.2 M€

Sales growth for the molecule of **+15%** mainly driven by the performance of licensing sales and those of the international subsidiaries, as well as strong performance in Portugal.

Mesalazine



17.0 M€

Mesalazine is the molecule with the highest percentage growth of **+59%** compared to 2024. In this case, growth is driven by the strong performance of the product licence in Poland.

All business areas trending positive


Revenues by business area

	9M 2025	9M 2024	%
Pharma	399.5	352.4	13%
Pharma Iberia	170.7	158.1	8%
Pharma International (without licenses)	129.6	109.2	9%
Pharma Licenses	99.2	85.1	17%
Animal Nutrition and Health	57.8	39.1	48%
Other*	-3.3	1.4	
Total	454.0	392.9	16%

* non-commercial income and exchange rate impact

Rounded data

Revenues by business area



Pharma business, solid growth in all lines

Total Pharma revenues: 399.5 M€ +13%

/01

IBERIA +8%

Growth sustained mainly by prescription. The incorporation in June of Laboratorio Edol, offset part of the slowdown in Portugal's growth.

/02

INTERNACIONAL +19%

Of note was the good performance of **LATAM +16%** and **ROW +23%** with overall growth in all markets, and the incorporation of SIFI in September.


/03

LICENSES +17%

Driven by the strong performance of **Bilastine +8%** with better-than-expected performance in Eastern European and Asia-Pacific countries, together with growth in **Other licences +55%**.

Pharma's revenues evolution in M€


Iberia*



International**



Licenses



*Spain and Portugal

**Without Licences or Portugal

Pharma Iberia, sustained growth in prescription

Iberia revenues: 170.7 M€ +8%

/01 SPAIN +1%

Prescription grew **+4%** with positive evolution especially in **bilastine +11%** thanks to new formats and the **respiratory franchise** which grew double digit **+19%** gaining competitiveness.


This growth offsets the slowdown in **Healthcare & consumer (-5%)**. In this area, a new strategy is being rolled out with a focus on priority brands to recover from this decline.

/02 PORTUGAL +44%


Growth mainly in prescription **+11%**, offsetting the performance of some Healthcare products. Incorporation in June of Laboratorio Edol, progressing at a good pace.

Revenues of Pharma Iberia in M€

Spain



Portugal



Pharma International, Latam as the growth engine

International revenues: 129.6 M€, +19%

/01

LATAM +16%


Colombia +25%, Ecuador +31% and Peru +25% y México +19% continued to perform very positively, with strong growth, based on the strategy of maximising the growth of our strategic products, bilastine and hidroferol.

Chile +6% growth in the retail market is growing in a good pace, offsetting the drop in the price of bilastine due to the strong presence of generics.


Central America-Caribbean grew **+8%**, reflecting the successful implementation of the action plan launched in the middle of the year.

Revenues of Pharma International in M€

LATAM



Rest of the world*



/02

ROW (Rest of the World) +23%

The effects of seasonal sales are diluted in this quarter, which will result in incremental revenue in subsequent quarters.

Completion of the acquisition of SIFI in September, adding one month of revenue.

Licences

Licences revenues: 99.2 M€ +17%

/01

BILASTINE +8%

Bilastine maintains the solid growth rate seen in previous quarters. The main drivers continue to be Eastern Europe and Asia-Pacific.

/02


OTHER LICENCES +55%

Performance in this area has been exceptional, driven mainly by strong growth in **Mesalazine**, which has consolidated its leadership in Poland with a 50% market share, as well as a notable increase in the Nordic countries.


Meanwhile, **Calcifediol** continues to expand strongly in Eastern Europe, exceeding initial forecasts, and has been successfully launched in new strategic markets such as Greece and Australia, both of which have high growth potential.

Licences revenues in M€

Bilastine



Other Licences



Animal nutrition and health

FARM Faes revenues: 57.8 M€ +48%


/01

Significant growth in revenue, with the **ISF** business as the main driver, with revenue continuing to exceed expectations.

FARM Faes strengthens its leadership in animal nutrition, especially in the piglet segment, thanks to the new ISF plant.

At the sector level, Chinese tariffs are putting downward pressure on the price of Spanish pork, adjusting the margins between selling price and production cost.

FARM Faes revenues in M€



3/

Results and outlook



Highlights 9M 2025

/01 – Income

Double-digit growth in the high end of the guidance driven by Farma International and licensing, demonstrating robust growth of the three strategic molecules. Incorporation of Edol in June and of SIFI in September.

/02 – Expenditure

- Increases in expenditure in line with the priorities of the strategic plan, as well as in expenses related to merger and acquisition operations.
- Incremental cost impact of the new Derio plant of 7.8M in 9 months.
- Increase in depreciation and amortisation due to the new production plants.

/03 EBITDA

- EBITDA (-2.7%) above the high end of guidance (-6%/-9%).
- Adjusted EBITDA* (+3%) in line with guidance.

*Adjusted EBITDA: ex M&A and excluding extraordinary costs from Derio

Results

Thousand €	9M 2025	9M 2024	%change
Ordinary income (sales)	440,953	379,535	16.2%
Other operating income	13,046	13,381	-2.5%
Tota Income	453,998	392,916	15.5%
Cost of sales	-153,572	-122,679	25.2%
Gross margin	300,426	270,237	11.2%
Personnel expenses	-89,445	-81,071	10.3%
Other operating expenses	-104,621	-79,713	31.2%
Gains (losses) on disposal of fixed assets	174	47	-
EBITDA	106,535	109,500	-2.7%
Adjusted EBITDA*	112,785	109,500	3.0%
Depreciation and impairment fixed assets	-18,646	-15,095	23.5%
EBIT	87,889	94,405	-6.9%
Financial gain/losses	-1,085	62	-
Profit before tax	86,804	94,468	-8.1%
Corporate tax	-13,179	-14,750	-10.7%
Net Profit	73,625	79,718	-7.6%
Profit to the Parent Company	73,561	79,843	-7.9%

Guides 2025 vs 9M 2025

Income 2025	Income 9M 2025
+8/10%	+15.5%
+10.6% excl. M&A	
EBITDA 2025	EBITDA 9M 2025
-6/-9%	-2.7%
Adjusted EBITDA* 2025	Adjusted EBITDA* 9M 2025
+3/5%	+3.0%

*Adjusted EBITDA: ex M&A and excluding extraordinary costs from Derio



Q&A



DISCLAIMER

This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an offer to sell or buy securities of Faes Farma.

The information contained in this presentation has not been independently verified and some of the information is in summary form. No representation or warranty, express or implied, is made by the Faes Pharma Group, its directors, officers, employees or representatives as to the fairness, accuracy, completeness or correctness of the information or opinions expressed in this document and it should not be relied upon as a reliable basis for investment decisions. Neither any member of the Faes Pharma Group nor any of its directors, officers, employees or representatives accepts any liability (whether for negligence or otherwise) for any loss, damage, cost or injury, whether direct or consequential, arising from the use of this presentation or its contents or otherwise in connection with the presentation. Except for any liability for fraud, Faes Pharma disclaims all liability, whether direct or indirect, express or implied, contractual, tortious, regulatory or otherwise, for the accuracy or completeness of the information in relation to the opinions contained in this document or for any errors, omissions or inaccuracies contained in this presentation.

Faes Pharma does not guarantee the accuracy or completeness of the information contained in this presentation. The information contained herein has been obtained from sources believed to be reliable by Faes Pharma, but Faes Pharma makes no representation or warranty as to its completeness or accuracy, particularly with respect to data provided by third parties.

This presentation contains information and statements or projections about Faes Pharma, S.A. Such statements include financial projections and estimates with underlying assumptions that are not historical facts. In this respect, although Faes Pharma, S.A. believes that the expectations reflected in such statements are reasonable, it warns that information and statements with forward-looking projections are subject to risks and uncertainties, known and unknown, which may cause the Group's business performance to differ from that expressed or implied and may affect its realisation.

Appendix

INCOME PHARMA IBERIA				INCOME INTERNACIONAL (without licences)				INCOME LICENCES				INCOME FARM FAES			
	9M 2025	9M 2024*	%var		9M 2025	9M 2024*	%var		9M 2025	9M 2024*	%var		9M 2025	9M 2024*	%var
Pharma Spain	133.3	132.1	1%	International	129.6	109.3	19%	Licences	99.2	85.1	17%	Animal health and nutrition	57.8	39.1	48%
Prescription	87.9	84.4	4%	9M 2025 9M 2024								Iberia		57.2	38.3
Bilastine	15.4	13.9		Subsidiaries LATAM	83.8	72.0	16%	Bilastine	76.3	70.3	8%	Subsidiaries LATAM		0.5	0.8
Calcifediol	31.3	30.9		Central American Caribbean	23.0	21.3		Other products	22.9	14.8	55%				
Mesalazine	5.1	5.2		Colombia	21.4	17.1									
Other products	36.1	34.4		Chile	14.4	13.6									
Healthcare & Consumer	45.3	47.7	-5%	Mexico	10.9	9.2									
				Ecuador	9.0	6.8									
				Peru	2.8	2.2									
Pharma Portugal	37.5	26.0	44%	Rest	2.3	1.8									
				9M 2025 9M 2024											
Faes Farma Portugal	24.9	26.0	-4%	ROW	45.8	37.3	23%								
Laboratorio Edol	12.5	0.0		Exportaciones ROW	25.2	25.6									
				Faes Gulf	4.8	5.0									
				Italia	8.5	6.4									
				Nigeria	0.5	0.4									
				SIFI	6.6	0.0									
Other non-commercial income	0.3	0.6		Exchange rate differences	-3.5	0.8									

*Minimal variations due to reorganisation in line with accounting criteria.